{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T05:10:05Z","timestamp":1749964205936,"version":"3.41.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s11886-017-0827-0","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T07:33:14Z","timestamp":1486625594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neprilysin Inhibitors in Cardiovascular Disease"],"prefix":"10.1007","volume":"19","author":[{"given":"Guson","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipanjan","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,9]]},"reference":[{"issue":"11","key":"827_CR1","doi-asserted-by":"publisher","first-page":"140830040023009","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, et al. Angiotensin\u2013Neprilysin inhibition versus Enalapril in heart failure. N Engl J Med. 2014;371(11):140830040023009. doi: 10.1056\/NEJMoa1409077 .","journal-title":"N Engl J Med"},{"issue":"11","key":"827_CR2","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1056\/NEJMe1409898","volume":"371","author":"M Jessup","year":"2014","unstructured":"Jessup M. Neprilysin inhibition--a novel therapy for heart failure. N Engl J Med. 2014;371(11):1062\u20134. doi: 10.1056\/NEJMe1409898 .","journal-title":"N Engl J Med"},{"issue":"11","key":"827_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMp1410241","volume":"371","author":"CA Sacks","year":"2014","unstructured":"Sacks CA, Jarcho JA, Curfman GD. Paradigm shifts in heart-failure therapy--a timeline. N Engl J Med. 2014;371(11):989\u201391. doi: 10.1056\/NEJMp1410241 .","journal-title":"N Engl J Med"},{"issue":"5788","key":"827_CR4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/288286a0","volume":"288","author":"BP Roques","year":"1980","unstructured":"Roques BP, Fourni\u00e9-Zaluski MC, Soroca E, et al. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature. 1980;288(5788):286\u20138. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7001254 . Accessed February 22, 2016.","journal-title":"Nature"},{"issue":"2","key":"827_CR5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0022-3565(25)22255-8","volume":"250","author":"EJ Sybertz","year":"1989","unstructured":"Sybertz EJ, Chiu PJ, Vemulapalli S, et al. SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. J Pharmacol Exp Ther. 1989;250(2):624\u201331. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2547941 . Accessed February 22, 2016.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"827_CR6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1042\/bj2430183","volume":"243","author":"SL Stephenson","year":"1987","unstructured":"Stephenson SL, Kenny AJ. The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J. 1987;243(1):183\u20137. http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=1147830&tool=pmcentrez&rendertype=abstract . Accessed February 22, 2016.","journal-title":"Biochem J"},{"issue":"11","key":"827_CR7","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1253\/circj.CJ-08-0130","volume":"72","author":"N Hata","year":"2008","unstructured":"Hata N, Seino Y, Tsutamoto T, et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure. Circ J. 2008;72(11):1787\u201393. doi: 10.1253\/circj.CJ-08-0130 .","journal-title":"Circ J"},{"issue":"1","key":"827_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1100171","volume":"365","author":"CM O\u2019Connor","year":"2011","unstructured":"O\u2019Connor CM, Starling RC, Hernandez AF. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32\u201343. doi: 10.1056\/NEJMoa1100171 .","journal-title":"N Engl J Med"},{"issue":"6","key":"827_CR9","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1161\/01.HYP.26.6.1160","volume":"26","author":"S-I Ando","year":"1995","unstructured":"Ando S-I, Rahman MA, Butler GC, Senn BL, Floras JS. Comparison of candoxatril and atrial natriuretic factor in healthy men : effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension. 1995;26(6):1160\u20136. doi: 10.1161\/01.HYP.26.6.1160 .","journal-title":"Hypertension"},{"issue":"9116","key":"827_CR10","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(05)77712-6","volume":"351","author":"JG Cleland","year":"1998","unstructured":"Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. Lancet. 1998;351(9116):1657\u20138. doi: 10.1016\/S0140-6736(05)77712-6 .","journal-title":"Lancet"},{"issue":"3","key":"827_CR11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00004872-199203000-00011","volume":"10","author":"JE O\u2019Connell","year":"1992","unstructured":"O\u2019Connell JE, Jardine AG, Davidson G, Connell JM. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens. 1992;10(3):271\u20137. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1315825 . Accessed March 1, 2016.","journal-title":"J Hypertens"},{"issue":"4","key":"827_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1527-3466.2000.tb00051.x","volume":"18","author":"G McDowell","year":"2006","unstructured":"McDowell G, Nicholls DP. The therapeutic potential of candoxatril, a neutral endopeptidase inhibitor, in humans. Cardiovasc Drug Rev. 2006;18(4):259\u201370. doi: 10.1111\/j.1527-3466.2000.tb00051.x .","journal-title":"Cardiovasc Drug Rev"},{"issue":"8","key":"827_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Califf RM, Konstam MA, et al. Comparison of Omapatrilat and Enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106(8):920\u20136. doi: 10.1161\/01.CIR.0000029801.86489.50 .","journal-title":"Circulation"},{"issue":"2","key":"827_CR14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","volume":"17","author":"JB Kostis","year":"2004","unstructured":"Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17(2):103\u201311. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14751650 . Accessed March 14, 2016.","journal-title":"Am J Hypertens"},{"issue":"9722","key":"827_CR15","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"Ruilope LM, Dukat A, B\u00f6hm M, Lacourci\u00e8re Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet (London, England). 2010;375(9722):1255\u201366. doi: 10.1016\/S0140-6736(09)61966-8 .","journal-title":"Lancet (London, England)"},{"issue":"4","key":"827_CR16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","volume":"63","author":"K Kario","year":"2014","unstructured":"Kario K, Sun N, Chiang F-T, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698\u2013705. doi: 10.1161\/HYPERTENSIONAHA.113.02002 .","journal-title":"Hypertension"},{"key":"827_CR17","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Bozkurt B, Butler J, Casey DE, et al. 2016 ACC\/AHA\/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure. doi: 10.1016\/j.cardfail.2016.07.001 . Last published guidelines for the medical management of heart failure.","DOI":"10.1016\/j.cardfail.2016.07.001"},{"key":"827_CR18","unstructured":"Ollendorf DA, Sandhu AT, Chapman R, et al. CardioMEMS HF System (St. Jude Medical) and Sacubitril\/Valsartan (Entresto, Novartis) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks. Institute for Clinical and Economic Review. https:\/\/icer-review.org\/wp-content\/uploads\/2016\/01\/CHF_Revised_Draft_Report_100915.pdf . Published 2015."},{"key":"827_CR19","unstructured":"Drug Finder: Find which 2017 Medicare Part D plans best covers your drugs. https:\/\/q1medicare.com\/PartD-SearchPDPMedicarePartDDrugFinder.php . Published 2016."},{"issue":"1","key":"827_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131","author":"M Packer","year":"2015","unstructured":"Packer M, McMurray JJV, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54\u201361. doi: 10.1161\/CIRCULATIONAHA.114.013748 .","journal-title":"Circulation"},{"issue":"16","key":"827_CR21","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147\u2013239. doi: 10.1016\/j.jacc.2013.05.019 .","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-017-0827-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-017-0827-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-017-0827-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T04:39:00Z","timestamp":1749962340000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-017-0827-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1007\/s11886-017-0827-0","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"type":"print","value":"1523-3782"},{"type":"electronic","value":"1534-3170"}],"subject":[],"published":{"date-parts":[[2017,2]]},"article-number":"16"}}